medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 4

<< Back Next >>

Ann Hepatol 2018; 17 (4)

New Insights About Albumin and Liver Disease

Carvalho JR, Verdelho MM

Language: English
References: 133
Page: 547-560
PDF size: 318.54 Kb.


ABSTRACT

Decompensated liver cirrhosis has a dismal prognosis, with an overall survival of 2-4 years, which is worse than for many oncological diseases. Albumin is an important tool in the management of patients with cirrhosis, since it decreases for less than half the risk for post-paracentesis cardiocirculatory dysfunction and mortality associated with spontaneous bacterial infection, as well as, it triplicates the response to terlipressin in patients with hepatorenal syndrome. Recently, research on albumin has been a hot topic, with important new insights such as the characterization of the pleiotropic effects of albumin (which surpass its oncotic properties) and the concept of effective albumin concentration. In fact, patients with liver cirrhosis present posttranslational modifications on albumin that compromises its function. Those modified albumin forms were proved to have prognostic value and its knowledge may change the paradigm of albumin treatment. In this review, we critically summarize the latest evidence on the potential benefits of albumin in patients with end-stage liver disease.


REFERENCES

  1. Tsochatzis E. Liver cirrhosis. Lancet 2014; 383: 1749-61.

  2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot- Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608.

  3. D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. J Hepatol 2006; 44: 217-31.

  4. Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H, Galeras JA, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385-94.

  5. Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: 810-8.

  6. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.

  7. Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. Ann Hepatol 2011; 10: 15-20.

  8. Dudley FJ. Pathophysiology of ascites formation. Gastroenterol Clin North Am 1992; 21: 215-35.

  9. John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol 2015; 21: 3197-205.

  10. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.

  11. Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, Laggetta M, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 2014; 60: 1851-60.

  12. Carballal S, Alvarez B, Turell L, Botti H, Freeman BA, Radi R. Sulfenic acid in human serum albumin. Amino Acids 2007; 32: 543-51.

  13. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013; 58: 1836-46.

  14. Stauber RE, Spindelboeck W, Haas J, Putz-Bankuti C, Stadlbauer V, Lackner C, Oettl K. Human nonmercaptalbumin-2: a novel prognostic marker in chronic liver failure. Ther Apher Dial 2014; 18: 74-8.

  15. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol 2014; 4: 302-11.

  16. Vincent JL, De Backer D, Wiedermann CJ. Fluid management in sepsis: The potential beneficial effects of albumin. J Crit Care 2016; 35: 161-7.

  17. Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996; 7: 125-37.

  18. Rassaf T, Preik M, Kleinbongard P, Lauer T, Heiss C, Strauer BE, Feelisch M, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest 2002; 109: 1241-8.

  19. Bernardi M, Predieri S. Disturbances of acid-base balance in cirrhosis: a neglected issue warranting further insights. Liver Int 2005; 25: 463-6.

  20. Valerio C, Theocharidou E, Davenport A, Agarwal B. Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. World J Hepatol 2016; 8: 345-54.

  21. Simon-Talero M, Garcia-Martinez R, Torrens M, Augustin S, Gómez S, Pereira G, Guevara M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 2013; 59: 1184-92.

  22. Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006; 12: 1403-7.

  23. Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med 2016; 9: 229-55.

  24. Prinsen BH, de Sain-van der Velden MG. Albumin turnover: experimental approach and its application in health and renal diseases. Clin Chim Acta 2004; 347: 1-14.

  25. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990; 37: 57-84.

  26. Era S, Ashida H, Nagaoka S, Inouye H, Sogami M. CD-resolved secondary structure of bovine plasma albumin in acid-induced isomerization. Int J Pept Protein Res 1983; 22: 333-40.

  27. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992; 358: 209-15.

  28. Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol 2013; 59: 918-20.

  29. Rossing N. Intra- and extravascular distribution of albumin and immunoglobulin in man. Lymphology 1978; 11: 138-42.

  30. Yoshida K, Seto-Ohshima A, Sinohara H. Sequencing of cDNA encoding serum albumin and its extrahepatic synthesis in the Mongolian gerbil, Meriones unguiculatus. DNA Res 1997: 4: 351-4.

  31. Nahon JL, Tratner I, Poliard A, Presse F, Poiret M, Gal A, Sala-Trepat JM, et al. Albumin and alpha-fetoprotein gene expression in various nonhepatic rat tissues. J Biol Chem 1988; 263: 11436-42.

  32. Dodson CS, Rengarajan K, Gewant HD, Stodulkova E, Nguyen HT, Boatright JH, Nickerson JM. Extra-hepatic expression of serum albumin mRNA in mouse retina. Curr Eye Res 2001; 22: 182-9.

  33. Sun X, Kaysen GA. Albumin and transferrin synthesis are increased in H4 cells by serum from analbuminemic or nephrotic rats. Kidney Int 1994; 45: 1381-7.

  34. Peavy DE, Taylor JM, Jefferson LS. Time course of changes in albumin synthesis and mRNA in diabetic and insulin-treated diabetic rats. Am J Physiol 198; 248: E656-63.

  35. Moshage HJ, de Haard HJ, Princen HM, Yap SH. The influence of glucocorticoid on albumin synthesis and its messenger RNA in rat in vivo and in hepatocyte suspension culture. Biochim Biophys Acta 1985; 824: 27-33.

  36. Kernoff LM, Pimstone BL, Solomon J, Brock JF. The effect of hypophysectomy and growth hormone replacement on albumin synthesis and catabolism in the rat. Biochem J 1971; 124: 529-35.

  37. Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 1995; 95: 39-45.

  38. Kleger GR, Turgay M, Imoberdorf R, McNurlan MA, Garlick PJ, Ballmer PE. Acute metabolic acidosis decreases muscle protein synthesis but not albumin synthesis in humans. Am J Kidney Dis 2001; 38: 1199-207.

  39. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-9.

  40. Yedgar S, Carew TE, Pittman RC, Beltz WF, Steinberg D. Tissue sites of catabolism of albumin in rabbits. Am J Physiol 1983; 244: 101-7.

  41. Grimm G, Haslacher H, Kampitsch T, Endler G, Marsik C, Schickbauer T, Wagner O, et al. Sex differences in the association between albumin and all-cause and vascular mortality. Eur J Clin Invest 2009; 39: 860-5.

  42. Fulks M, Stout RL, Dolan VF. Albumin and all-cause mortality risk in insurance applicants. J Insur Med 2010; 42: 11-7.

  43. Takata Y, Ansai T, Soh I, Awano S, Sonoki K, Akifusa S, Kagiyama S, et al. Serum albumin levels as an independent predictor of 4-year mortality in a community-dwelling 80-year-old population. Aging Clin Exp Res 2010; 22: 31-5.

  44. Umeki Y, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Nakao E, et al. Serum Albumin and Cerebro-cardiovascular Mortality During a 15-year Study in a Community-based Cohort in Tanushimaru, a Cohort of the Seven Countries Study. Intern Me 2016; 55: 2917-25.

  45. Tanaka F, Komi R, Makita S, Onoda T, Tanno K, Ohsawa M, Itai K, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens 2016; 34: 506-12; discussion 512.

  46. Corti MC, Guralnik JM, Salive ME, Sorkin JD. Serum albumin level and physical disability as predictors of mortality in older persons. Jama 1994; 272: 1036-42.

  47. Nguyen MK, Kurtz I. Determinants of plasma water sodium concentration as reflected in the Edelman equation: role of osmotic and Gibbs-Donnan equilibrium. Am J Physiol Renal Physiol 2004; 286: 828-37.

  48. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007; 151: 580-90.

  49. Anraku M, Chuang VT, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim Biophys Acta 2013; 1830: 5465-72.

  50. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000; 85: 599-610.

  51. Zhang WJ, Frei B. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res 2002; 55: 820-9.

  52. Bar-Or D, Thomas GW, Bar-Or R, Rael LT, Scarborough K, Rao N, Shimonkevitz R. Commercial human albumin preparations for clinical use are immunosuppressive in vitro. Crit Care Med 2006; 34: 1707-12.

  53. Doguet F, Tamion F, Le Guillou V, Bubenheim M, Thuillez C, Richard V, Bessou JP. Albumin limits mesenteric endothelial dysfunction and inflammatory response in cardiopulmonary bypass. Artif Organs 2012; 36: 962-71.

  54. Lang JD, Jr., Figueroa M, Chumley P, Aslan M, Hurt J, Tarpey MM, Alvarez B, et al. Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium. Anesthesiology 2004; 100: 51-8.

  55. Bortoluzzi A, Ceolotto G, Gola E, Sticca A, Bova S, Morando F, Piano S, et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 2013; 57: 266-76.

  56. Oettl K, Marsche G. Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol 2010; 474: 181-95.

  57. Colombo G, Clerici M, Giustarini D, Rossi R, Milzani A, Dalle- Donne I. Redox albuminomics: oxidized albumin in human diseases. Antioxid Redox Signal 2012; 17: 1515-27.

  58. Candiloros H, Muller S, Ziegler O, Donner M, Drouin P. Role of albumin glycation on the erythrocyte aggregation: an in vitro study. Diabet Med 1996; 13: 646-50.

  59. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011; 93: 645-58.

  60. Vlassopoulos A, Lean ME, Combet E. Role of oxidative stress in physiological albumin glycation: a neglected interaction. Free Radic Biol Med 2013; 60: 318-24.

  61. Bar-Or D, Rael LT, Bar-Or R, Slone DS, Craun ML. The formation and rapid clearance of a truncated albumin species in a critically ill patient. Clin Chim Acta 2006; 365: 346-9.

  62. Naldi M, Giannone FA, Baldassarre M, Domenicali M, Caraceni P, Bernardi M, Bertucci C. A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur J Mass Spectrom (Chichester) 2013; 19: 491-6.

  63. Pieters BJ, Fibuch EE, Eklund JD, Seidler NW. Inhaled Anesthetics Promote Albumin Dimerization through Reciprocal Exchange of Subdomains. Biochem Res Int 2010; 2010: 516704.

  64. Dengler TJ, Robertz-Vaupel GM, Dengler HJ. Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 1992; 43: 491-9.

  65. Jaisson S, Delevallee-Forte C, Toure F, Rieu P, Garnotel R, Gillery P. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Lett 2007; 581: 1509-13.

  66. Watanabe H, Imafuku T, Otagiri M, Maruyama T. Clinical Implications Associated With the Posttranslational Modification-Induced Functional Impairment of Albumin in Oxidative Stress-Related Diseases. J Pharm Sci 2017; 106: 2195-03.

  67. Sogami M, Nagoka S, Era S, Honda M, Noguchi K. Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 1984; 24: 96-103.

  68. Turell L, Botti H, Carballal S, Ferrer-Sueta G, Souza JM, Durán R, Freeman BA, et al. Reactivity of sulfenic acid in human serum albumin. Biochemistry 2008; 47: 358-67.

  69. Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I, Suzuki E, et al. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. Febs j 2006; 273: 3346-57.

  70. Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med 2005: 33: 1638-41.

  71. Luna C, Alique M, Navalmoral E, Noci MV, Bohorquez-Magro L, Carracedo J, Ramírez R. Aging-associated oxidized albumin promotes cellular senescence and endothelial damage. Clin Interv Aging 2016; 11: 225-36.

  72. Claria J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology 2016; 64: 1249- 64.

  73. Bosoi CR, Rose CF. Oxidative stress: a systemic factor implicated in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2013; 28: 175-8.

  74. Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, et al. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stressrelated chronic diseases. PLoS One 2014; 9: e85216.

  75. Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, Putz-Bankuti C, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 2013; 59: 978-83.

  76. Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S. Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004; 20: 351-7.

  77. Das S, Maras JS, Hussain MS, Sharma S, David P, Sukriti S, Shasthry SM, et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology 2017; 65: 631-46.

  78. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallström S, Lackner C, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008; 1782: 469-73.

  79. Giannone FA, Domenicali M, Baldassarre M, Bartoletti M, Naldi M, Laggetta M, Bertucci C, et al. Ischaemia-modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver Int 2015; 35: 2425-32.

  80. Baldassarre M, Domenicali M, Naldi M, Laggetta M, Giannone FA, Biselli M, Patrono D, et al. Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. Sci Rep 2016; 6: 35987.

  81. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Sitespecific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995; 227: 524-8.

  82. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, Muravsky V, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555- 64.

  83. Chen CY, Tsai WL, Lin PJ, Shiesh SC. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med 2011; 49: 1817-21.

  84. Cakir M, Karahan SC, Mentese A, Sag E, Cobanoglu U, Polat TB, Erduran E. Ischemia-modified albumin levels in children with chronic liver disease. Gut Liver 2012; 6: 92-7.

  85. Kumar PA, Subramanian K. The Role of Ischemia Modified Albumin as a Biomarker in Patients with Chronic Liver Disease. J Clin Diagn Res 2016; 10: Bc09-12.

  86. Yavuz F, Biyik M, Asil M, Dertli R, Demir A, Polat H, Uysal S, et al. Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis Brelated chronic liver diseases. Turk J Med Sci 2017; 47: 947-53.

  87. Naldi M, Baldassarre M, Nati M, Laggetta M, Giannone FA, Domenicali M, Bernardi M, et al. Mass spectrometric characterization of human serum albumin dimer: A new potential biomarker in chronic liver diseases. J Pharm Biomed Anal 2015; 112: 169-75.

  88. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. Ann Intensive Care 2013; 3: 4.

  89. Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem 1984; 259: 3812-7.

  90. Taguchi K, Chuang VT, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. J Pharm Sci 2012; 101: 3033-46.

  91. Rothschild MA, Oratz M, Zimmon D, Schreiber SS, Weiner I, Van Caneghem A. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-(14)C. J Clin Invest 1969; 48: 344-50.

  92. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology 2005; 41: 1211-9.

  93. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32: 157-70.

  94. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.

  95. BA R. Practice guideline - Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. American Association for The Study of Liver Diseases - AASLD 2012; 1-96.

  96. Guevara M, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, Arroyo V, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 2012; 57: 759-65.

  97. Thevenot T, Bureau C, Oberti F, Anty R, Louvet A, Plessier A, Rudler M, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015; 62: 822-30.

  98. Sharma BC, Singh J, Srivastava S, Sangam A, Mantri AK, Trehanpati N, Sarin SK. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol 2017; 32: 1234-9.

  99. Vila MC, Sola R, Molina L, Andreu M, Coll S, Gana J, Marquez J, et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol 1998; 28: 639-45.

  100. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.

  101. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55: 1172-81.

  102. Salo J, Gines A, Gines P, Piera C, Jiménez W, Guevara M, Fernández-Esparrach G, et al. Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997; 27: 645-53.

  103. Moller S, Henriksen JH, Bendtsen F. Ascites: pathogenesis and therapeutic principles. Scand J Gastroenterol 2009; 44: 902-11.

  104. Gines P, Tito L, Arroyo V, Planas R, Panés J, Viver J, Torres M, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.

  105. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, Angeli P, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.

  106. Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008; 28: 43-58.

  107. Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int 2010; 30: 937-47.

  108. Chen RP, Chen C, Yu JY, Huang XL, Zhou MT, Huang ZM. Trial sequence meta-analysis can reject false-positive result calculated from conventional meta-analysis. Hepatology 2014; 60: 1442-3.

  109. Kutting F, Schubert J, Franklin J, Bowe A, Hoffmann V, Demir M, Pelc A, et al. Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC-free cirrhotic patients undergoing large volume paracentesis. J Gastroenterol Hepatol 2017; 32: 327-38.

  110. Alessandria C, Elia C, Mezzabotta L, Risso A, Andrealli A, Spandre M, Mogando A, et al. Prevention of paracentesisinduced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis 2011; 43: 881-6.

  111. Hussain W, Khalid AB, Usmani T, Ghufran A, Shah H. Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis. Pak J Med Sci 2015; 31: 592-6.

  112. Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M, Rabe C, Lammert F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008; 28: 1019-25.

  113. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103: 1399-405.

  114. Hamdy H, ElBaz AA, Hassan A, Hassanin O. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. J Clin Gastroenterol 2014; 48: 184-8.

  115. Guo TT, Yang Y, Song Y, Ren Y, Liu ZX, Cheng G. Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis. J Dig Dis 2016; 17: 11-9.

  116. Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, Sharma AK. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006; 260: 62-8.

  117. Moreau R, Asselah T, Condat B, Kerguenec C, Pessione F, Bernard B, Poynard T, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-4.

  118. Lata J, Marecek Z, Fejfar T, Zdenek P, Brùha R, Safka V, Hùlek P, et al. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites—a randomized multicentric study. Hepatogastroenterology 2007; 54: 1930-3.

  119. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-501.

  120. Ruiz-del-Arbol L, Urman J, Fernandez J, González M, Navasa M, Monescillo A, Albillos A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8.

  121. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruizdel- Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.

  122. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11: 123-30.e1.

  123. Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56: 597-9.

  124. Poca M, Concepcion M, Casas M, Alvarez-Urturi C, Gordillo J, Hernández-Gea V, Román E, et al. Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2012; 10: 309-15.

  125. de Araujo A, de Barros Lopes A, Rossi G, Veber da Silva G, Ananias P, Ness S, Álvares-da-Silva MR, et al. Lowdose albumin in the treatment of spontaneous bacterial peritonitis: should we change the standard treatment? Gut 2012; 61: 1371-2.

  126. Salman TA, Edrees AM, El-Said HH, El-Abd OL, El-Azab GI. Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016; 28: 777-85.

  127. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl. 1): S1-12.

  128. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62: 968-74.

  129. Ortega R, Gines P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002: 36: 941-8.

  130. Martin-Llahi M, Pepin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.

  131. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.

  132. Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA, Moon YS. Renal Dysfunction Induced by Bacterial Infection other than Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: Incidence and Risk Factor. Gut Liver 2009; 3: 292-7.

  133. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 223-9.




2020     |     www.medigraphic.com